Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Azilsartan Medoxomil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 known ✓ | P30556 | 3/20 | 0.50 |
| ▸ | AGTR2 | P50052 | 4/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.50 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.50 |
| ▸ | PPARG | P37231 | 2/20 | 0.50 |
| ▸ | HTR2B | P41595 | 2/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.50 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.46 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 0.46 |
| ▸ | SLCO1B1 | Q9Y6L6 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azilsartan Medoxomil SCHEMBL29861385 | 0.90 | AGTR2 (1.00) | AGTR2CYP3A4AGTR1PDE3AABCB11 | |
| Azilsartan Medoxomil SCHEMBL683374 | 0.90 | AGTR2 (1.00) | AGTR2CYP3A4AGTR1PDE3AABCB11 | |
| Azilsartan Medoxomil SCHEMBL30770646 | 0.89 | AGTR2 (0.99) | AGTR2CYP3A4AGTR1PDE3AABCB11 | |
| Azilsartan Medoxomil SCHEMBL967313 | 0.89 | AGTR2 (0.99) | AGTR2CYP3A4AGTR1PDE3AABCB11 | |
| Azilsartan Medoxomil SCHEMBL965772 | 0.89 | AGTR2 (0.99) | AGTR2CYP3A4AGTR1PDE3AABCB11 | |
| SCHEMBL683315 | 0.89 | AGTR2 (0.79) | AGTR2CYP3A4AGTR1PDE3AABCB11 | |
| Azilsartan Medoxomil SCHEMBL968583 | 0.89 | AGTR2 (0.99) | AGTR2CYP3A4AGTR1PDE3AABCB11 | |
| Azilsartan Medoxomil SCHEMBL967309 | 0.89 | AGTR2 (0.99) | AGTR2CYP3A4AGTR1PDE3AABCB11 | |
| Azilsartan Medoxomil SCHEMBL965769 | 0.89 | AGTR2 (0.99) | AGTR2CYP3A4AGTR1PDE3AABCB11 | |
| SCHEMBL2132264 | 0.88 | AGTR2 (0.63) | AGTR2CYP3A4AGTR1PDE3AABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10300471-B2 | Ruthenium-catalyzed synthesis of biaryl compounds in water | CHICAGO DISCOVERY SOLUTIONS, LLC | 2019-05-28 | — | — | US | disclosed |
| US-20160263565-A1 | RUTHENIUM-CATALYZED SYNTHESIS OF BIARYL COMPOUNDS IN WATER | CHICAGO DISCOVERY SOLUTIONS, LLC (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160263565-A1 | RUTHENIUM-CATALYZED SYNTHESIS OF BIARYL COMPOUNDS IN WATER | CHICAGO DISCOVERY SOLUTIONS, LLC (US) | 2016-09-15 | — | — | US | disclosed |
| WO-2015054120-A1 | RUTHENIUM-CATALYZED SYNTHESIS OF BIARYL COMPOUNDS IN WATER | CHICAGO DISCOVERY SOLUTIONS, LLC (US) | 2015-04-16 | — | — | WO | disclosed |
| EP-2068812-B9 | MEDICINAL PACKAGE | TAKEDA PHARMACEUTICAL (JP) | 2012-08-08 | — | — | EP | disclosed |
| US-20120100093-A1 | MEDICINAL PACKAGE | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-04-26 | — | — | US | disclosed |
| US-20090308780-A1 | Medicinal package | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10300471-B2 | Ruthenium-catalyzed synthesis of biaryl compounds in water | RUVBL2, RUVBL1, CYP2W1 | AGTR1 372/4885AGTR2 265/4885CYP3A4 77/4885 |
| US-20160263565-A1 | RUTHENIUM-CATALYZED SYNTHESIS OF BIARYL COMPOUNDS IN WATER | RUVBL2, RUVBL1, CYP2W1 | AGTR1 372/4885AGTR2 265/4885CYP3A4 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.